TokenPost·
EyePoint Expects COMO, CAPRI Phase 3 Data in Early Q4 2027
The company is focusing its Phase 3 program on DURAVYU for diabetic macular edema.
More news
- TokenPostJim Cramer Urges Nvidia Investors to Take Profits After Huang Resigns
- TokenPostPaul Meeks Calls Nvidia’s Valuation ‘Stupid’ and Says He’s Buying Shares
- TokenPostSolana Says AKT Linked to @akashnet Is Live Through Sunrise
- TokenPostU.S. Crude Inventories Rose by 4.657 Million Barrels in Weekly Data
- Crypto BriefingNvidia stock downgraded as CEO Jensen Huang resigns, CFO Kress interim chief
- crypto.newsKalshi ends Trump Jr. advisory deal over Polymarket investment